scholarly journals Case Report : A Woman 27 Year Old with Mosaic Turner Syndrome Associate Hypogonadotropic Hypogonadism

2020 ◽  
Vol 1 (2) ◽  
pp. 42-47
Author(s):  
Cennikon Pakpahan ◽  
Bella Amanda ◽  
Berliana Hamidah ◽  
Rina Yudiwati

Background: Turner syndrome is a chromosomal abnormality found in phenotypically women who have one intact X chromosome and the absence of second sex chromosomes. Case: The patient is a 27-year-old Javanese girl. At the age of 14 years, she came to the gynecology clinic with chief complaints of amenorrhea and then given cycloprogynova by the physcian, the complaint improved but menstruation did not appear in the following month did not return to the gynecologist  for evaluation. At the age of 26, she returned to the gynecologist and then was given medicine to stimulate menstruation and  was referred to an internist-endocrinologist because of  a suspected hypothyroid. Then a few months later the patient returned to the gynecologist and then examined hormones, ultrasound, and karyotyping for evaluation as well as establishing the diagnosis. FT4 hormone examination results 0.87 ng / dl, TSHs 0.708 Uiu / mL, T3 (Total) 0.49 ng / mL, FSH 2.38 Miu / mL, LH 1.3 Miu / mL, prolactin 14.7 ng / ml, progesterone <0.10 ng / ml, estradiol <5 ng / ml indicates hypogonadotropic hypogonadism with hypothyroidism. Ultrasound results showed hypoplasia with uterine axis measuring 2.27 x 2.09 cm. Karyotyping result with 45x / 46xx indicate mosaic turner syndrome. Patients were given progestin, esthero and also thyrax for hormone replacement therapy. Discussion: Turner syndrome with hypogonadotropic hypgonadism is a rare variation of the turner syndrome. The definite cause is still uncertain. Some cases are usually accompanied by other hormone disorders such as thyroid and growth hormone. Conclusion: A 27-year-old woman with hypgonadotrophic hypgonadism associated with mosaic turner syndrome. The diagnosis is done by history taking, hormone examination, imaging, and karyotyping. treatment given progestin, estrogen, and thyrax.

2020 ◽  
Vol 11 ◽  
Author(s):  
Sabine Elisabeth Segerer ◽  
Stephan Georg Segerer ◽  
Carl-Joachim Partsch ◽  
Wolfgang Becker ◽  
Frank Nawroth

ObjectiveTurner syndrome (TS) is characterized by complete or partial loss of one sex chromosome and is commonly associated with short stature, metabolic changes (such as central obesity, abnormal glucose tolerance and high triglycerides) and premature ovarian insufficiency (POI). Primary management of TS during childhood and adolescence comprises treatment with human growth hormone (hGH) and, in cases with early loss of ovarian function, hormone replacement therapy (HRT). Given that metabolic parameters are altered when HRT is applied during menopause, we analyzed whether metabolic changes might be positively or negatively affected within 10 years after HRT and/or hGH in girls with TS.DesignObservational study.MethodsData were collected from the medical records of 31 girls with TS attending two endocrinologic centers in Germany between 2000 and 2020. Descriptive statistics are reported as the mean ± SEM or percentages.ResultsThe mean age at first presentation was 99.06 ± 8.07 months, the mean height was 115.8 ± 3.94 cm, and the mean BMI 19.0 ± 0.99 was kg/m2. Treatment with hGH was given to 96.8% of the girls, starting at an average age of 99.06 ± 8.70 months, and was continued for 67.53 ± 6.28 months. HRT was administered to 80.6% of all patients and was started at a mean age of 164.4 ± 4.54 months. During the follow-up, we did not observe any significant absolute changes in lipid parameters, but we detected beneficial effects of childhood hGH: significantly lower cholesterol (-0.206/month; p = 0.006), lower low density lipoprotein cholesterol (-0.216/month; p = 0.004), and higher high density lipoprotein cholesterol (+0.095/month; p = 0.048). Insulin concentrations, showed a significant increase attributable to hGH treatment (+0.206/month; p = 0.003), which was ameliorated by concomitant or subsequent HRT (-0.143/month; p = 0.039).ConclusionTreatment with hGH and HRT is provided to most girls with TS. Metabolic effects are associated with both modalities. Monitoring of metabolic changes appears to be important to detect unfavorable effects, and could guide treatment adjustment and duration.


2016 ◽  
Vol 60 (6) ◽  
pp. 596-600 ◽  
Author(s):  
Natasha G. Ludwig ◽  
Rafael F. Radaeli ◽  
Mariana M. X. Silva ◽  
Camila M. Romero ◽  
Alexandre J. F. Carrilho ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document